Clinical trials: psoriasis
Plaque Psoriasis
Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis
This study was a real-life study which was based on secondary data collection from the electronic or paper medical records from the Dermatology Clinics of the 14 University, Training \& Research Hospitals in Turkey.
- Trial name
- NCT05344482
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 277 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source
This was a retrospective, observational study of psoriasis patients treated with secukinumab, using secondary data from BADBIR. BADBIR is a UK/ROI pharmacovigilance registry that was initiated in 2007 to monitor the long-term…
- Trial name
- NCT05368818
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 767 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis.
- Trial name
- NCT03850483
- Testing
- PF-06700841
- Where
- 79 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- Pfizer
DLQI, PHQ-9
To Evaluate the Mechanism of Jing Si Herbal Tea Liquid Packets and Traditional Western Medicine for Psoriasis
Psoriasis is a chronic cutaneous inflammatory disease due to immune dysregulation. It caused skin lesions with thickening plaques and heavy silver scales over the patient's body surface area, including nail deformity, often…
- Conditions
- DLQI, PHQ-9, PSAI, Serum Cytokine Survey
- Trial name
- NCT05436938
- Testing
- Jing Si herbal tea liquid packets use
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Plaque Psoriasis
CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with moderate to severe plaque psoriasis will relieve signs and symptoms of the disease.
- Trial name
- NCT03168256
- Testing
- CF101 2mg, CF101 3mg, Apremilast 30mg
- Where
- 30 sites in Bosnia and Herzegovina, Bulgaria and 7 more
- Volunteers
- 528 people
- Sponsor
- Can-Fite BioPharma
Plaque Psoriasis
Evaluation of the Effect of Sulphur Mineral, Thermal Water on Skin Microbiome in Plaque Psoriasis, a Pilot Study
In this study the effects of balneotherapy in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal, mineral water on skin microbiome and Psoriasis Area and Severity Index…
- Trial name
- NCT05431959
- Testing
- balneotherapy
- Where
- 2 sites in Hungary
- Volunteers
- 16 people
- Sponsor
- Szeged University
Psoriasis
Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum Chitotriosidase Level in Psoriasis
The aim of the study is to evaluate the effect of NB-UVB versus MTX on serum Chitotriosidase level in psoriatic patients.
- Trial name
- NCT05427175
- Testing
- Narrowband ultraviolet B, Methotrexate
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Aswan University Hospital
Psoriasis Vulgaris, Psoriasis
Impact of Non-surgical Periodontal Therapy in the Management of Plaque Psoriasis.
Both periodontitis and plaque psoriasis are non communicable chronic inflammatory diseases. They share genetic polymorphysms (IL-1, IL-6 e TNFalfa) and risk factors (smoking, diabetes, obesity), as well as a great resemblance in…
- Conditions
- Psoriasis Vulgaris, Psoriasis, Periodontitis
- Trial name
- NCT05311501
- Testing
- Non-surgical periodontal treatment
- Where
- Italy
- Volunteers
- 74 people
- Sponsor
- University of Siena
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis who have not been previously treated with DMARDs.
- Trial name
- PALACE4 (NCT01307423)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 118 sites in United States, Australia and 16 more
- Volunteers
- 529 people
- Sponsor
- Amgen
Localized Psoriasis
Intralesional Injection Of Methotrexate Versus Triamcinolone Acetonid In Treatment Of Localized Psoriasis
The aim of the present study is to evaluate the efficacy of intralesional injection of methotrexate in comparison with Intralesional Injection of Triamcinolone Acetonid in localized psoriasis (body surface area < 10%) .
- Trial name
- NCT05408208
- Testing
- Intralesional Injection of Methotrexate, Triamcinolone Acetonid
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sohag University
Psoriasis
Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment
The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.
- Trial name
- DCE (NCT05065762)
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan
The purpose of this study is to understand current real-world treatment patterns and clinical outcomes, reasons for switching treatment, and participant characteristics using each systemic psoriasis treatment in Japan.
- Trial name
- NCT04826536
- Where
- Japan
- Volunteers
- 114 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
Effect of Acitretin Versus Narrowband Ultraviolet B on Neopterin Level in Psoriatic Patients .
To evaluate effect of acitretin versus Narrowband UVB on serum level of neopterin in psoriatic patients.
- Trial name
- NCT05401006
- Testing
- Acitretin 25Mg Cap, Narrowband ultraviolet B
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- South Valley University
Moderate to Severe Plaque Psoriasis
An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis
BCD-085 is an innovative drug, a monoclonal antibody against interleukin-17. The toxicity, safety, and pharmacokinetics of BCD-085 were investigated in animals, in phase I clinical study in healthy volunteers, and in phase III…
- Trial name
- BCD-085-7 (NCT03390101)
- Testing
- BCD-085 Q2W, BCD-085 Q4W
- Where
- Russia
- Volunteers
- 213 people
- Sponsor
- Biocad
Psoriasis
Utility of Squamous Cell Carcinoma Antigen (SCCA) in Psoriasis
Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation.
- Trial name
- SCCAPSO (NCT04308616)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Tours
Plaque Psoriasis
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
The purpose of this study is to assess the efficacy, safety and tolerability of Tildrakizumab in moderate-to-severe plaque psoriasis participants who are non-responder to Dimethyl fumarate (DMF) at Week 16.
- Trial name
- TRANSITION (NCT04263610)
- Testing
- Dimethyl fumarate (DMF) standard scheme, Dimethyl fumarate (DMF) simplified scheme, Tildrakizumab
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 190 people
- Sponsor
- Almirall, S.A.
Psoriasis Vulgaris
Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy
This study was performed to evaluate the safety, tolerability, activity, pharmacokinetics (PK), and daily dose regimen of KD025 administered orally (PO) for 12 weeks to subjects with psoriasis vulgaris who failed at least one…
- Trial name
- NCT02317627
- Testing
- KD025
- Where
- 9 sites in United States
- Volunteers
- 38 people
- Sponsor
- Kadmon Corporation, LLC
Diabetes, Psoriasis
Diabetes and Psoriasis
Patients with psoriasis will be evaluated. The investigators will collect personal history, concomitant diseases and in particular the presence of type 2 diabetes mellitus, impaired fasting glucose and impaired glucose…
- Trial name
- NCT02366273
- Testing
- PASI and HOMA index
- Where
- Italy
- Volunteers
- 425 people
- Sponsor
- University of Pavia
Psoriasis
Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)
Protocol Title: A Phase 1, first-in-human, randomized, double-blind, single-dose, parallel-group, 3-arm study comparing the pharmacokinetic, safety, tolerability, and immunogenicity profiles of AVT04, EU approved Stelara®, and…
- Trial name
- NCT04744363
- Testing
- Stelara PFS
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Alvotech Swiss AG
The Impact of COVID19 on Psoriasis Patients
Impact of COVID 19 on Psoriasis Patients
The main objective of this work is to investigate the effect of COVID-19 pandemic on psoriasis patients. This work is designed as a cross-sectional survey based on a questionnaire directed to Egyptian psoriasis patients.
- Trial name
- NCT05381402
- Testing
- Questionnaire
- Volunteers
- 230 people
- Sponsor
- Cairo University